Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Janssen, MacroGenics sign second pact
by Lisa M. Jarvis
May 23, 2016
| A version of this story appeared in
Volume 94, Issue 21
Janssen, the pharmaceutical arm of Johnson & Johnson, will pay MacroGenics $75 million to license the bispecific antibody MGD015. In preclinical studies, MGD015 blocks both CD3 and an undisclosed tumor target with the goal of redirecting T cells to kill cells that overexpress the undisclosed antigen. This is the second pact between Janssen and MacroGenics. The companies are already developing MGD011, a bispecific molecule targeting CD19 and CD3, as a blood cancer treatment.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter